Major thalassemia. Beta thalassaemia
Conditions
Interventions
Intervention 1: Intervention:In this group, 25 patients are put on a new irainian drug e
Osferal, and then it's side effect that is "lens opacity", will be compared with that of the control group. Intervention 2: Control:Based on the present policy, 25 patients who receive Deferoxamine an
Treatment - Drugs
Intervention:In this group, 25 patients are put on a new irainian drug e
Osferal, and then it's side effect that is "lens opacity", will be compared with that of the control group.
Control:Based on the present policy, 25 patients who receive Deferoxamine and have a known percent of "lens opacity", are considered as the control group.
Sponsors
Vice chancellor for research Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Years to 14 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: children having major thalassemia , being candidate for chelator therapy because of iron overload Exclusion criteria: diabetes mellitus and rheumatologic diseases, any lens disease or chelator therapy before the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lens opacity. Timepoint: After one year. Method of measurement: Ophthalmologic examinations. | — |
Secondary
| Measure | Time frame |
|---|---|
| Age- Gender- Family history. Timepoint: One year. Method of measurement: Answer sheet. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVahid Falahati
Imam Reza hospital, KUMS
Outcome results
None listed